A195in a hypothetical ten-million member health plan over a 3-year horizon. Estimates of plan cancer rates and utilization of HEC and MEC therapies were derived from epidemiological and market data. Treatment costs were computed using standard prescribing dosages, U.S. drug cost listings and simple reimbursement and dispensing assumptions. Uptake of NEPA was calculated at 5% a year for 3 years, and competing antiemetic therapies were reduced proportionately based on initial share assumptions. RESULTS: A total of 54,000 patients with cancer were identified in the model scenario. Of these, 9,882 (18.3%) would receive HEC and 3,949 (7.3%) would receive MEC requiring combination therapy, for a total of 13,830 eligible for NEPA. Cost of CINV prevention prior to the adoption of NEPA was estimated at $40.96 million. Following adoption of NEPA, cumulative costs were reduced by nearly $652K by the end of year 3. Calculations using PMPM estimates showed cumulative savings of $0.002 in year 1, $0.004 in year 2, and $0.005 in year 3. CONCLUSIONS: Results of the model indicate that adoption of NEPA for the prevention of CINV may have a relatively neutral impact on a U.S. health plan budget. Additionally, these estimates do not include savings from a potential reduction in the overall rate of CINV.

(2020): Costeffectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants, Human Vaccines & Immunotherapeutics,

Our findings indicate that local ASCs protected the bronchial stump after pneumonectomy and induced local changes in gene expression related to their protective action. These results could lead to a potential new therapeutic modality for the prevention of BPF.

It is estimated that the prevalence of moderate-to-severe SA (apnoeahypopnoea index > 15/h) is 10%. Approximately 11% of SA patients have comorbid COPD, which worsens sleep quality and desaturations. This study investigated the effects of PAP therapy on all-cause mortality and cost of illness (COI) in patients with SA and COPD in Germany. A statutory health insurance (SHI) perspective was taken. Methods: A total of > 4 million individuals covered by the SHI database were analysed (≈5% of the German SHI population). PAP therapy was initiated in 4,068 patients with SA (PAP group). Propensity score matching was used to define a control group (CG) of 4,068 SA patients matched for age, sex, risk factors/aetiology, region and medication who received usual care (no PAP). Of these, 1,300 patients in the PAP group and 1,192 patients in the CG had comorbid COPD. This subgroup of patients was followed for 3 years after initiation of PAP therapy. Results: Total COI was higher in the PAP group versus CG in the first year of follow-up (€ 8,697 vs € 6,999, p< 0.0001). However, during the second and third year the difference in COI between the PAP and CG was smaller (year 2: € 7,340 vs € 7,316, p< 0.0048; year 3: € 6,847 vs € 6,714, p< 0.001). PAP recipients had a significantly lower 3-year mortality rate compared with CG (8.2% vs 11.7%, p< 0.001; relative risk reduction 30.1%). ConClusions: SA patients with COPD treated with PAP showed significantly reduced mortality and morbidity. Total COI was higher in PAP recipients versus CG over the first 3 years of follow-up, but the difference between groups decreased over time. A follow-up period of ≥ 5 years may be required to show beneficial economic outcomes in SA patients receiving PAP therapy.

A407patients received medical services to the value of 927 million Euro or 14.2% of total reimbursed lump-sums (6.53 billion Euros) in Austria. 224 million Euros fall upon medical tumour therapy. With regard to monoclonal antibody therapies, 56 million Euros was refunded. ConClusions: The current development in modern cancer therapies leads to efficient treatment pathways expressed in higher survival rates, reduced hospital days and an improved quality-of-life.